{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:32:54Z","timestamp":1763051574196,"version":"3.45.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.soc.2025.04.006","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:27:43Z","timestamp":1748611663000},"page":"133-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Chemoradiotherapy for Pancreatic Adenocarcinoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Sylvia S.W.","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheron","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie G.","family":"Coburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.soc.2025.04.006_bib1","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1200\/JCO.2007.15.5556","article-title":"Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.soc.2025.04.006_bib2","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.soc.2025.04.006_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.soc.2025.04.006_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"issue":"10073","key":"10.1016\/j.soc.2025.04.006_bib5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.soc.2025.04.006_bib6","first-page":"1240","article-title":"Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial","volume":"43","author":"Palmer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.soc.2025.04.006_bib7","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.soc.2025.04.006_bib8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.04.006_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00000658-199302000-00008","article-title":"Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy","volume":"217","author":"Willett","year":"1993","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.soc.2025.04.006_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00000658-199506000-00011","article-title":"Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients","volume":"221","author":"Yeo","year":"1995","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.soc.2025.04.006_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00000658-199501000-00007","article-title":"Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?","volume":"221","author":"Nitecki","year":"1995","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.soc.2025.04.006_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/bjs.1800830512","article-title":"Survival after resection for ductal adenocarcinoma of the pancreas","volume":"83","author":"Sperti","year":"1996","journal-title":"Br J Surg"},{"issue":"7","key":"10.1016\/j.soc.2025.04.006_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/000313489906500704","article-title":"Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas","volume":"65","author":"Millikan","year":"1999","journal-title":"Am Surg"},{"issue":"3","key":"10.1016\/j.soc.2025.04.006_bib14","first-page":"263","article-title":"Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas","volume":"52","author":"Benassai","year":"2000","journal-title":"Chir Ital"},{"issue":"6","key":"10.1016\/j.soc.2025.04.006_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","article-title":"Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators","volume":"4","author":"Sohn","year":"2000","journal-title":"J Gastrointest Surg"},{"issue":"2","key":"10.1016\/j.soc.2025.04.006_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1091-255X(01)80023-8","article-title":"Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas","volume":"5","author":"Pingpank","year":"2001","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"10.1016\/j.soc.2025.04.006_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/bjs.5397","article-title":"Redefining the R1 resection in pancreatic cancer","volume":"93","author":"Verbeke","year":"2006","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.soc.2025.04.006_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.sla.0000259391.84304.2b","article-title":"Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma","volume":"246","author":"Raut","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2025.04.006_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/1097-0142(19850715)56:2<397::AID-CNCR2820560232>3.0.CO;2-I","article-title":"Pancreatic cancer. assessment of prognosis by clinical presentation","author":"Kalser","year":"1985","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.soc.2025.04.006_bib20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.soc.2025.04.006_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/SLA.0b013e318156eef3","article-title":"Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891","volume":"246","author":"Smeenk","year":"2007","journal-title":"Ann Surg"},{"issue":"9293","key":"10.1016\/j.soc.2025.04.006_bib22","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.soc.2025.04.006_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2004.11.018","article-title":"A challenge to the therapeutic nihilism of ESPAC-1","volume":"61","author":"Koshy","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.soc.2025.04.006_bib24","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/sj.bjc.6602513","article-title":"Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer","volume":"92","author":"Stocken","year":"2005","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.soc.2025.04.006_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","article-title":"Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial","volume":"299","author":"Regine","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.soc.2025.04.006_bib26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","article-title":"Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial","volume":"18","author":"Regine","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.04.006_bib27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2010.11.039","article-title":"Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas","volume":"82","author":"Abrams","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.soc.2025.04.006_bib28","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.ijrobp.2012.04.035","article-title":"Five year results of US intergroup\/RTOG 9704 with postoperative CA 19-9 \u226490 U\/mL and comparison to the CONKO-001 trial","volume":"84","author":"Berger","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.soc.2025.04.006_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ijrobp.2014.07.024","article-title":"Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer","volume":"90","author":"Morganti","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"29","key":"10.1016\/j.soc.2025.04.006_bib30","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.04.006_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1245\/s10434-009-0743-7","article-title":"Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study","volume":"17","author":"Hsu","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.04.006_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/COC.0000000000000633","article-title":"Results of the NRG Oncology\/RTOG 0848 adjuvant chemotherapy question-erlotinib+gemcitabine for resected cancer of the pancreatic head: a phase ii randomized clinical trial","volume":"43","author":"Abrams","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.soc.2025.04.006_bib33","article-title":"NRG Oncology\/RTOG0848: results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periamullary pancreatic adenocarcinoma","volume":"42","author":"Abrams","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.04.006_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/00000658-200112000-00007","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial","volume":"234","author":"Neoptolemos","year":"2001","journal-title":"Ann Surg"},{"issue":"21","key":"10.1016\/j.soc.2025.04.006_bib35","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2007.15.8469","article-title":"Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the johns hopkins hospital","volume":"26","author":"Herman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.04.006_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archsurg.2007.17","article-title":"Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials","volume":"143","author":"Butturini","year":"2008","journal-title":"Arch Surg"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532072500050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532072500050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:28:09Z","timestamp":1763051289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105532072500050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S105532072500050X"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.04.006","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Chemoradiotherapy for Pancreatic Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}